Table S4.
Comparison of mean human plasma pharmacokinetic parameters following topical ocular and oral single- and multiple-dose exposures of olopatadine
| Pharmacokinetic parameters | Single-dose
|
Multiple-dose
|
||
|---|---|---|---|---|
| Olopatadine 0.77% (n=24) |
10 mg olopatadine oral tablet (n=8)1 | Olopatadine 0.77% (n=22) |
10 mg olopatadine oral tablet (n=8)1 | |
| Cmax, ng/mL (SD) | 1.88 (0.99) | 131.10 (19.36) | 1.64 (0.89) | 146.82 (44.37) |
| Tmax, hours (SD) | 1.74 (1.10) | 1.44 (0.50) | 2.08 (1.69) | 1.56 (0.50) |
| AUC0–12, ng⋅h/mL (SD) | 9.79 (4.02) | 426 (68) | 9.68 (4.42)* | 479 (81.00)** |
| AUC0–∞, ng⋅h/mL (SD) | 10.6 (4.32) | 455 (61) | 10.8 (4.83)* | ND |
| t1/2, hours (SD) | 2.90 (0.98) | 10.50 (1.38) | 3.40 (1.20) | 11.47 (2.95) |
Notes:
*
n=19.
**
n=4. AUC0–12, area under the plasma concentration–time curve from 0 to 12 hours; Cmax, peak plasma concentration; Tmax, time to reach maximum plasma concentration; t1/2, elimination half-life.
Abbreviations: ND, not determined; SD, standard deviation.